Editas Medicine Announces Third Quarter 2021 Results and Business Updates
EDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enrollment ongoing in adult high-dose and pediatric mid-dose cohorts
EDIT-301 Phase 1/2 RUBY trial for the treatment of sickle cell disease currently enrolling study participants
Presented preclinical data on novel SLEEK gene editing technology enabling high efficiency, multi-transgene knock-in in multiple clinically relevant cell types
“Editas recently marked an important milestone with the presentation of initial EDIT-101 results demonstrating a favorable safely profile and encouraging signals of clinical activity and evidence of ocular gene editing. Encouraged by these data, we look forward to obtaining additional clinical results, including from our ongoing adult high-dose and pediatric mid-dose cohorts,” said
Recent Achievements and Outlook
- EDIT-101 for Leber Congenital Amaurosis 10 (LCA10), a CEP290-Related Retinal Degenerative Disorder
Initial clinical data demonstrated favorable safety profile, and efficacy signals in the mid-dose cohort provided initial evidence for clinical benefit
Editas Medicinepresented initial clinical data from the ongoing, open label Phase 1/2 BRILLIANCE clinical trial of EDIT-101 for the treatment of LCA10. The data included preliminary patient safety and efficacy assessments on the first two cohorts.
No serious adverse events or dose-limiting toxicities were reported in the first six adult subjects treated with the low or mid doses of EDIT-101. In addition, early efficacy signals in the mid dose cohort provided clinical evidence of gene editing and suggest potential clinical benefits. The Company believes these initial data validate Editas Medicine’s in vivo platform’s proof of concept and provide support for the advancement of the adult high-dose cohort and the pediatric mid-dose cohort. The Company will continue to assess patients in the adult low-dose and mid-dose cohorts while it enrolls and treats patients in the adult high-dose and pediatric mid-dose cohorts. The Company remains on track to complete dosing of the adult high-dose and pediatric mid-dose cohorts in the first half of 2022.
- EDIT-301 for Sickle Cell Disease
Enrolling patients for initial dosing
The Company is developing EDIT-301 for the treatment of sickle cell disease.
Editas Medicineuses a proprietary engineered CRISPR/Cas12a ribonucleoprotein (RNP) to edit the HBG1/2 promoter mimicking a benign and naturally occurring human fetal hemoglobin mutation. This site is a naturally validated location, as patients with Hereditary Persistence of Fetal Hemoglobin (HPFH) harbor the sickle cell mutation but do not exhibit symptoms of the disease. The Company believes that targeting this site is potentially a more effective approach with better long-term safety than editing the BCL11A enhancer. The Phase 1/2 RUBY trial for the treatment of sickle cell disease is currently enrolling study participants and expects to begin dosing in the first half of 2022.
- EDIT-301 for Transfusion-Dependent Beta Thalassemia (TDT)
Preclinical data supporting potential treatment for TDT to be presented at ASH
The Company will present preclinical data on EDIT-301 for the treatment of transfusion-dependent beta thalassemia at the 63rd
American Society of HematologyAnnual Meeting & Exposition (ASH). The data will demonstrate that edited beta thalassemia CD34+ cells show significant improvement in erythroid maturation and health, accompanied by significantly increased total hemoglobin content per cell. These data support the hypothesis that editing of the HBG1/2 promoter using an engineered AsCas12a RNP may reverse red blood cell abnormalities associated with the disease and increase hemoglobin production. The Company believes that EDIT-301 has the potential to be an efficacious autologous cell therapy for TDT and remains on track to file an IND by year-end.
- Edited iPSC NK (iNK) Cell Medicines to Treat Solid Tumors
Preclinical data demonstrating multiplexed gene editing and tumor clearance to be presented at SITC and ASH
Editas Medicineis continuing to advance preclinical studies for a highly differentiated, iPSC-derived natural killer (iNK) cell medicine. At the upcoming Society for Immunotherapyof Cancer’s 36th Anniversary Annual Meeting, the Company will present data demonstrating a new method to drive high-level constitutive CD16 expression, which enhances antibody-dependent cell-mediated cytotoxicity (ADCC) of iNK cells, enabling improved serial tumor killing. This was achieved through transgene knock-in using the Company’s engineered AsCas12a and new SLEEK (SeLection by Essential-gene Exon Knock-in) gene editing technology. These data provide evidence for the potential of the iNK program to exert enhanced anti-tumor activity in the clinic.
At ASH, the Company will present data showing that iNK cells, edited with CRISPR/Cas12a to knock out CISH and TGFβR2, demonstrated robust anti-tumor efficacy resulting in a three-fold reduction in tumor burden compared to unedited iNK cell treatment. This potent anti-tumor activity is maintained after cryopreservation and supports further development, potentially with additional gene edits, of the iNK program as a potent allogeneic cell-based medicine for cancer.
- Alpha-Beta T Cells for Oncology
Bristol Myers Squibb opting into additional program
Editas Medicineand Bristol Myers Squibb (BMS) continue to advance alpha-beta T cell medicines for the treatment of solid and liquid tumors. BMS recently opted into an additional gene editing program, further validating the Company’s technology and expertise in engineered cell medicines. This marks the fourth program, one of which has advanced to development candidate status, opted into by BMS in the last twelve months.
Gene Editing Platform
The Company also presented preclinical data at the
Editas Medicineappointed Emma Reeveto its Board of Directors and as Chairperson of the Audit Committee. Ms. Reeveis an accomplished biopharmaceutical executive with more than 25 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies. Most recently, Ms. Reeveserved as Chief Financial Officer of Constellation Pharmaceuticals, Inc., a development-stage oncology company, prior to its acquisition by MorphoSys AG in 2021. Prior to Constellation, Ms. Reeveacted as interim Chief Financial Officer and Corporate Controller of Parexel International, a global biopharmaceutical services company. Earlier in her career, Ms. Reeveserved as Chief Financial Officer of both Inotek Pharmaceuticals and Aton Pharma. Additionally, she held senior finance and operational roles at Bristol-Myers Squibb, Merck, and Novartis.
In October, the Company also appointed
Bernadette Connaughtonto its Board of Directors. Ms. Connaughtonis an accomplished pharmaceutical executive with more than 30 years of global strategic, commercial, and biopharmaceutical industry expertise. Ms. Connaughtonspent her career at Bristol-Myers Squibb, building a consistent track record of achieving sales growth, improving operational models, and increasing profitability in the U.S., Europe, and Asia. She most recently served as President Intercontinental. In this role, she developed successful, multi-year commercialization strategies for several oncology, virology, and immunology products.
Third Quarter 2021 Financial Results
- Cash, cash equivalents, and marketable securities as of
September 30, 2021, were $657.0 million, compared to $698.1 millionas of June 30, 2021. The Company expects that its existing cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditures well into 2023.
- For the three months ended
September 30, 2021, net loss attributable to common stockholders was $39.1 million, or $0.57per share, compared to net income of $7.8 million, or $0.13per share, for the same period in 2020.
- Collaboration and other research and development revenues were
$6.2 millionfor the three months ended September 30, 2021, compared to $62.8 millionfor the same period in 2020. The $56.6 milliondecrease was primarily attributable to the recognition of $59.9 millionof previously deferred revenue as a result of the termination of our strategic alliance with Allergan during the third quarter 2020 for which there was no similar revenue recognized in the third quarter of 2021.
- Research and development expenses decreased by
$4.7 millionto $29.2 millionfor the three months ended September 30, 2021, from $33.9 millionfor the same period in 2020. The $4.7 milliondecrease related primarily to a one-time in-process research and development expense of $5.0 millionfor re-acquiring the rights to EDIT-101 from Allergan in the third quarter of 2020 for which there was no similar expense in the third quarter of 2021.
- General and administrative expenses decreased by
$3.7 millionto $16.2 millionfor the three months ended September 30, 2021, from $19.9 millionfor the same period in 2020. The $3.7 milliondecrease was primarily attributable to decreased professional service expenses during the third quarter of 2021.
Society for Immunotherapy of Cancer(SITC) 36th Annual Meeting, November 10 - 14, Washington, D.C.
American Society of Hematology(ASH) Annual Meeting & Exposition, December 11 - 14, Atlanta, Georgia
- Barclays Gene Editing & Gene Therapy Summit,
November 15, Virtual
- 4th Annual
Evercore ISI HealthCONx Conference, December 2, Virtual
As a leading genome editing company,
EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder. EDIT-101 is administered via a subretinal injection to reach and deliver the gene editing machinery directly to photoreceptor cells.
The BRILLIANCE Phase 1/2 clinical trial of EDIT-101 for the treatment of Leber congenital amaurosis 10 (LCA10) is designed to assess the safety, tolerability, and efficacy of EDIT-101 in up to 18 patients with this disorder. Clinical trial sites are enrolling up to five cohorts testing up to three dose levels in this open label, multi-center study. Both adult and pediatric patients (3 – 17 years old) with a range of baseline visual acuity assessments are eligible for enrollment. Patients receive a single administration of EDIT-101 via subretinal injection in one eye. Patients are monitored every three months for a year after dosing and less frequently for an additional two years thereafter. Additional details are available on www.clinicaltrials.gov (NCT#03872479).
EDIT-301 is an experimental, autologous cell therapy medicine under investigation for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). EDIT-301 is comprised of sickle patient (for SCD) or normal donor (for TDT) CD34+ cells genetically modified using a highly specific and efficient CRISPR/Cas12a (also known as Cpf1) ribonucleoprotein (RNP) that targets the HBG1 and HBG2 promoters in the beta-globin locus where naturally occurring fetal hemoglobin (HbF) inducing mutations reside. Red blood cells derived from EDIT-301 CD34+ cells demonstrate a sustained increase in HbF production, which has the potential to provide a one-time, durable treatment benefit for people living with sickle cell disease and TDT.
The RUBY Trial is a single-arm, open-label, multi-center Phase 1/2 study designed to assess the safety and efficacy of EDIT-301 in patients with severe sickle cell disease. Enrolled patients will receive a single administration of EDIT-301. Additional details are available on www.clinicaltrials.gov (NCT#04853576).
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical and clinical studies and its research and development programs, including completing dosing of both the adult high-dose and pediatric mid-dose cohorts in the first half of 2022 and beginning patient dosing in the RUBY trial in the first half of 2022, the timing for the Company’s receipt and presentation of data from its clinical trials and preclinical studies, the timing or likelihood of regulatory filings and approvals, including filing an IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia by the end of 2021, and the Company’s expectations regarding cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials, including the BRILLIANCE and RUBY trials, and clinical development of the Company’s product candidates; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the
Condensed Consolidated Statements of Operations
(amounts in thousands, except per share and share data)
|Three Months Ended|
|Collaboration and other research and development revenues||$||6,197||$||62,841|
|Research and development||29,265||33,916|
|General and administrative||16,185||19,936|
|Total operating expenses||45,450||53,852|
|Operating (loss) income:||(39,253||)||8,989|
|Other income (expense), net:|
|Other income (expense), net||19||(1,396||)|
|Interest income, net||152||226|
|Total other income (expense), net||171||(1,170||)|
|Net (loss) income||$||(39,082||)||$||7,819|
|Net (loss) income per share, basic||$||(0.57||)||$||0.13|
|Net (loss) income per share, diluted||$||(0.57||)||$||0.12|
|Weighted-average common shares outstanding, basic||68,219,742||62,144,118|
|Weighted-average common shares outstanding, diluted||68,219,742||62,697,173|
Selected Condensed Consolidated Balance Sheet Items
(amounts in thousands)
|Cash, cash equivalents, and marketable securities||$||657,039||$||511,774|
|Deferred revenue, net of current portion||60,888||73,984|
|Total stockholders’ equity||586,794||393,586|
Source: Editas Medicine, Inc.